Skip to Main Content
Contribute Try STAT+ Today

Way back in January, Thermo Fisher Scientific (TMO), the world’s largest maker of scientific tools, monitored the speedy sequencing in China of an unnamed coronavirus that would soon blaze around the world. Gearing up to produce diagnostic test kits and keep hospitals and labs supplied with the instruments to read them, the Waltham, Mass.-based company raced to deliver 5 millions tests per week by mid-April, as did two other giants in biopharma, Roche (RHHBY) and Abbott (ABT).

Now Thermo Fisher’s goal is 10 million per week. Shortages of supplies needed to make or interpret the tests have eased. Looking ahead to the fall, the company expects new arenas for its testing will create new demand. Businesses have begun to test — and retest — their returning employees. Schools, colleges, and universities plan to test their students and staff. Even professional sports leagues want to repeatedly test athletes competing in events where they can’t be socially distant.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.